Clinical trial approval / initiation

Explore the landscape of Clinical trial approval / initiation in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial approval / initiation to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Taienkang Pharma Subsidiary HABKSON Wins NMPA Approval for Diquafosol Sodium Eye Drops – Generic Dry Eye Therapy Enters RMB 228 Million Chinese Ophthalmic Market
CompanyDrug

Taienkang Pharma Subsidiary HABKSON Wins NMPA Approval for Diquafosol Sodium Eye Drops – Generic Dry Eye Therapy Enters RMB 228 Million Chinese Ophthalmic Market

Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that its wholly‑owned subsidiary Shandong HABKSON Biotechnology Co., Ltd. ("HABKSON") has received a Drug Registration Certificate from China's National Medical Products Administration…

Livzon Pharma Wins Approval for China's First 3‑Month Leuprorelin Microsphere – Long‑Acting GnRH Agonist Cuts Injection Frequency by 70% Across Breast Cancer, Prostate Cancer, and Precocious Puberty

Livzon Pharma Wins Approval for China’s First 3‑Month Leuprorelin Microsphere – Long‑Acting GnRH Agonist Cuts Injection Frequency by 70% Across Breast Cancer, Prostate Cancer, and Precocious Puberty

Hybio Pharmaceutical's AI‑Designed Triple Agonist HY3003 Clears FDA IND Filing for Obesity – GLP‑1/GIP/Glucagon Tri‑Target Drug Outperforms Tirzepatide and Retatrutide in Preclinical Weight Loss

Hybio Pharmaceutical’s AI‑Designed Triple Agonist HY3003 Clears FDA IND Filing for Obesity – GLP‑1/GIP/Glucagon Tri‑Target Drug Outperforms Tirzepatide and Retatrutide in Preclinical Weight Loss

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

CanSino Biologics Receives NMPA Approval for Haemophilus influenzae type B (Hib) Conjugate Vaccine Clinical Trial

CompanyDrug

Hengrui Pharmaceuticals Gets Green Light from NMPA for Two Anti-Cancer Drugs

CompanyDrug

Sichuan Biokin Gets NMPA Green Light for BL-B01D1 ADC in NSCLC Clinical Trial

CompanyDrug

ImmuneOnco Receives NMPA Approval for Phase III Clinical Trial of CD47 Inhibitor TIMDARPACEPT

CompanyDrug

Shanghai Henlius Biotech Advances TIGIT-Targeting HLX53 to Phase II Clinical Trial for Hepatocellular Carcinoma

CompanyDrug

Innovent Biologics’ IBI133 Receives Tacit Approval for Clinical Trial from China’s CDE

CompanyDrug

Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial

CompanyDrug

Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment

Show More